CRISPR Therapeutics' gene therapy for sickle cell disease and beta-thalassemia gets FDA approval, boosting biotech stocks.

CRISPR Therapeutics AG (CRSP), a gene-editing company, has received FDA approval for its gene therapy CASGEVY, which treats sickle cell disease and beta-thalassemia. The biotech sector is expected to grow by 13% in 2025, driven by favorable interest rate policies and heightened investor interest. Meanwhile, Avantax Advisory Services invested $269,000 in CRSP recently. A comparison with MeiraGTx shows CRSP is more affordable but riskier, with higher institutional ownership. Both companies focus on gene therapies for serious diseases.